Finding · criterion S5
What should a seller disclose about cold shipping?
A shipping promise should identify storage instructions, the responsible pharmacy, and the route for resolving a temperature concern. Delivery speed alone cannot establish product quality.
Fast delivery is only one detail
A storefront may promise overnight shipping or insulated packaging without explaining the medicine's storage requirements. Those are different statements. Shipping speed describes transport time; product-specific instructions address conditions relevant to the supplied preparation.
FDA has received complaints about compounded GLP-1 products arriving warm or with inadequate cooling. The agency recommends not using injectable GLP-1 drugs that arrive warm or inadequately refrigerated. A delivery concern belongs with the dispensing pharmacy and prescribing clinician rather than a seller's general marketing reassurance.
The useful evidence travels with the order
The prescription label, pharmacy name, tracking history, packaging, and photographs of the delivery can help identify what arrived and when. A lot number or other product identifier makes a complaint more specific. A statement about one product cannot establish the shipping tolerance of every formulation offered by the same brand.
Brand-name medicines and compounded preparations should not inherit one another's instructions by assumption. Even similar-looking containers can contain different concentrations or formulations. Product-specific directions and a response from the dispensing pharmacy are more useful than a general assertion that peptides are stable.
A public policy should explain responsibility
A clear seller policy identifies whom to contact, how a delivery problem is documented, and how replacement requests are considered. It should distinguish a clinical product concern from a carrier delay and from a routine cancellation. These details let a reader understand the process before an order exists.
The ledger currently does not assign a separate cold-shipping score. The presence of a laboratory report under S5 also does not verify transportation. This is an additional documentation question, and a missing public policy should be described as missing information rather than proof that the seller's shipments failed.
A complete product record connects the seller, prescriber, pharmacy, and delivered label. When those names cannot be reconciled, the documentation gap remains relevant even if the package arrived promptly.
Related standard: S5. Analytical documentation. Evidence for individual companies appears in the seller ledger.
Related reading
Sources
Related findings
Does a peptide certificate of analysis prove sterility?A purity result does not establish sterility. A certificate supports only the tests performed on the identified sample, using the stated methods.
Which laboratories sign the research vendors' test reports?A handful of laboratories sign most of the reports, few of them state an accreditation on their own sites, and some vendors credit a laboratory on the homepage that signs none of their documents.
The state of the Standard, edition 1Eight criteria applied to every record, each reported as its own pass, fail and not-verified count, split between telehealth services and research vendors. No criterion is summed with another, and no record is scored.
The criterion the licensed services fail and the research vendors passAlmost the whole split runs one way. The sellers operating outside the prescription system publish more laboratory evidence than the licensed services do, with exceptions on both sides named on the page. The split is structural rather than a difference in care, and a certificate is a document about one lot, not an approval.